AstraZeneca’s R&D Restructuring Follows Hot Spot Trend
This article was originally published in The Pink Sheet Daily
Executive Summary
In its most ambitious overhaul since the reorganization into iMeds in 2010, AstraZeneca’s latest R&D restructuring takes on three basic challenges: accessing innovation, improving internal productivity and reducing complexity and cost. It is the opening salvo in the new CEO’s vision for the troubled pharma.